Polidocanol Versus Glucose Treatment of Telangiectasia Trial (PG3T)

• ClinicalTrials.gov Identifier: NCT02657252
• Recruitment Status: Completed
• First Posted: January 15, 2016
• Results First Posted: November 28, 2017
• Last Update Posted: January 4, 2018
• Sponsor: UPECLIN HC FM Botucatu Unesp
• Collaborator: Fundação de Amparo à Pesquisa do Estado de São Paulo
• Information provided by (Responsible Party): Dr Matheus Bertanha, UPECLIN HC FM Botucatu Unesp

Study Description

Brief Summary:

It will be done a randomized triple-blind study comparing 0,2% polidocanol versus 75% hypertonic glucose of sclerotherapy in lower limbs´ telangiectasis. It will be included only adult women with reticular veins on the side of the thighs and mild venous insufficiency (CEAP 1). The primary endpoint will be efficacy, and secondary will be safety.

Condition or disease	Intervention/treatment	Phase
Varicose Veins; Telangiectasis	Drug: Glucose; Drug: Polidocanol with Glucose	Phase 4

Detailed Description:

Background. The prevalence of chronic venous disease is high in the general population, mainly in young women, and in milder cases the usual complaint is aesthetic. Various techniques are used for treatment of mild varicose disease, including surgical treatment, laser ablation and sclerotherapy. Telangiectasis are those with less than 1 mm diameter, reddish and important contribution to the aesthetic damage, and sometimes they are related to local pain. There is no consensus in the literature about the effectiveness of treatment with sclerotherapy, despite of being an usual procedure with different chemicals.

Methods and design. One hundred lower limbs of healthy women between 18 and 65 years will be triple blind randomized to receive treatment with polidocanol 0.2% diluted in 70% hypertonic glucose versus 75% hypertonic glucose for sclerotherapy treatment of telangiectasis. The patients will be examined and clinically classified. It will be included patients with telangiectasis sited at out's thigh, and only one extremity will be included per patient. The patients with varicose disease CEAP 2 or more will not be included. The treatment will be carried out in only one session and the medication volume not exceeding 5 ml. Clinical follow-up protocols will be filled on regular visits on days 0 - 7 - 60 concomitantly with photograph documentation. Supplementary examination for venous mapping with ultrasound pretreatment is performed for all patients.

Discussion. This prospective controlled double-blind randomized trial aims to verify and compare the efficacy and safety for sclerotherapy treatment of telangiectasis of the lower limbs. The results may help physicians to choose the best sclerotherapy treatment for telangiectasis.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 115 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Polidocanol Versus Glucose For Sclerotherapy Treatment Of Telangiectasia Of The Lower Limbs: Protocol For A Randomized, Controlled Clinical Trial
• Study Start Date: January 2015
• Actual Primary Completion Date: September 2016
• Actual Study Completion Date: November 2016

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Glucose; An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects	Drug: Glucose; Sclerotherapy of telangiectasis in one lower limb.; Other Name: Hypertonic dextrose
Active Comparator: Polidocanol with Glucose; An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects	Drug: Polidocanol with Glucose; Sclerotherapy of telangiectasis in one lower limb.; Other Names: Asclera; Varithena

Outcome Measures

Primary Outcome Measures :

1. Change From Baseline in Extent of Telangiectasias [ Time Frame: 2 months ]
   Efficiency in promoting the disappearance of the treated telangiectasias, making the comparison between the initial measurements in centimeters and after two months, then comparing the treatment between the two treatments

Secondary Outcome Measures :

1. Skin Hyperpigmentation [ Time Frame: 2 months ]
   Observed after two months of treatment the occurrence of hyperpigmentation stains in the treated areas. Measuring in centimeters those stains and compare the two treatments together.
2. Number of Participants With Deep Venous Thrombosis (DVT) [ Time Frame: 1 week ]
   Observe after one week of treatment occurred if clinical signs and symptoms of deep vein thrombosis (DVT) and perform duplex ultrasound for confirmation. Compare the results between the two groups to establish a security policy.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• females
• with telangiectasis on thigh side
• clinical classification of chronic venous disease C1(mild venous disease),
• minimum age of 18 year-old and maximum age 65 year-old
• agreement with the study
• signing the free and informed consent ( IC)
• not use anticoagulant drugs .

Exclusion Criteria:

• male
• varicose disease in any quantity or location with clinical classification of chronic venous disease different of C1(mild venous disease)
• restrict mobility
• arterial insufficiency
• be allergic to any substance that may be related to the study drugs
• any cause of dermatitis on application site
• don´t be free of comorbidities clinically serious as diabetes mellitus, heart failure, respiratory failure, uncontrolled hypertension with medication, and uncontrolled hypothyroidism
• pregnancy
• previous deep vein thrombosis (DVT)
• family history of DVT
• thrombophilia
• do not agree with the search terms

Contacts and Locations

Locations

Brazil

Vascular Lab

Botucatu, São Paulo, Brazil, 18618687

Sponsors and Collaborators

UPECLIN HC FM Botucatu Unesp

Fundação de Amparo à Pesquisa do Estado de São Paulo

Investigators

• Principal Investigator: Matheus Bertanha, Dr; Botucatu School of Medicine

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Bertanha M, Camargo PA, Moura R, Yoshida WB, Pimenta RE, Mariuba JV, Alcantara GP, de Paula DR, Sobreira ML. Polidocanol versus glucose in the treatment of telangiectasia of the lower limbs (PG3T): Protocol for a randomized, controlled clinical trial. Medicine (Baltimore). 2016 Sep;95(39):e4812. doi: 10.1097/MD.0000000000004812.

• Responsible Party: Dr Matheus Bertanha, Assistant professor, UPECLIN HC FM Botucatu Unesp
• ClinicalTrials.gov Identifier: NCT02657252
• Other Study ID Numbers: UPECLIN
• First Posted: January 15, 2016
• Results First Posted: November 28, 2017
• Last Update Posted: January 4, 2018
• Last Verified: November 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes

Keywords provided by Dr Matheus Bertanha, UPECLIN HC FM Botucatu Unesp:

telangiectasis; varicose veins; veins; glucose; sclerotherapy

Additional relevant MeSH terms:

Telangiectasis; Varicose Veins; Vascular Diseases; Cardiovascular Diseases; Polidocanol; Sclerosing Solutions; Pharmaceutical Solutions